AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comSEP 291 min read$JNJ

BofA Raises J&J Target but Sees Q3 Earnings 12% Below Street

BofA Securities raised its price target for Johnson & Johnson (JNJ) to $278 from $263, maintaining a Neutral rating. The firm expects Q3 sales of $25.5B, aligning with consensus, and EPS of $2.53, 12% below Street estimates. JNJ shares were down 0.22% in premarket trading.

Original reporting
finance.yahoo.com
Published Sep 29, 2026, 12:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 29, 2026, 1:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
BofA Raises J&J Target but Sees Q3 Earnings 12% Below Street — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$JNJNeutralMed
01

Why it matters

The analyst's actions create a nuanced signal: higher valuation but weaker near‑term earnings.

02

Market read

Provides fresh guidance that could move JNJ stock in the near term.

03

What to watch

Potential impact of in‑process R&D charges on future profitability.

Relevance 7/10Novelty 7/10Timing: premarket today

Background

BofA Securities updated its valuation model for JNJ, raising the price target while lowering its Q3 earnings estimate.

Company-level read

Ticker impact

$JNJNeutralHigh confidence
Context

BofA raised its price target on Johnson & Johnson to $278 and cut its Q3 EPS estimate 12% below Street.

Expected impact

mixed pressure as investors weigh the higher target against the lower earnings outlook

Evidence & confidence

Analyst upgrade provides a fresh catalyst, yet the earnings downgrade may limit upside.

Market effects

Sector

Defensive health sector may see modest re‑rating as analysts adjust earnings expectations.

Regional

U.S. large‑cap health stocks could experience slight volatility.

Global

Limited to investors tracking major pharma stocks.

Counterpoint

What could challenge this read

The EPS downgrade may outweigh the target raise, suggesting a short‑term pullback.

Key entities

  • company
    Johnson & Johnson

    U.S. healthcare conglomerate

  • analyst
    BofA Securities

    Bank of America research unit

Read at source← All news

Related articles

SEP 29
$JNJMed

Johnson & Johnson's psoriasis drug Icotyde could hit $4.5B in peak sales, BofA says

Bank of America raised its peak sales estimate for Johnson & Johnson's (JNJ) psoriasis drug Icotyde to $4.5B, up from $2.4B, and increased its price target to $278. The broker forecasts $70M in Q3 sales and $220M in 2026 sales, with limited changes to companywide 2026 sales forecasts. JNJ's earnings estimates were adjusted to reflect recent acquisitions and collaborations, with a Q3 EPS forecast of $2.53, below the consensus of $2.87.

proactiveinvestors.com2 min
SEP 29
$JNJMedAI 9/10

Johnson & Johnson Reports IMAAVY Myasthenia Gravis Data

Johnson & Johnson (JNJ) presented two-year data from its Vibrance-MG study, showing sustained benefits in adolescents with generalized myasthenia gravis (gMG) treated with IMAAVY. Improvements in daily function and muscle strength were maintained, with no new safety concerns. A separate survey indicated that 73.2% of adults who switched to IMAAVY from other treatments reported significant improvements.

grafa.com2 min
SEP 29
$JNJMedAI 8/10

Icotrokinra Shows Sustained Psoriasis Benefits at 1 Year

Johnson & Johnson's icotrokinra (Icotyde) showed sustained benefits in treating moderate-to-severe plaque psoriasis over one year, with high rates of skin clearance and symptom improvement. The FDA approved the drug in March. Results from the ICONIC-ADVANCE trials were published in the British Journal of Dermatology, showing 73%-78% of participants achieving clear or almost clear skin at week 52.

medscape.com3 min